Effect of zoledronate on avascular necrosis of the femoral head according to disease stage and bone resorption activity
Moksi, Lotta; Sissala, Niko; Ojala, Risto; Lehenkari, Petri; Valkealahti, Maarit (2026-02-08)
Biomed central
08.02.2026
Moksi, L., Sissala, N., Ojala, R., Lehenkari, P., & Valkealahti, M. (2026). Effect of zoledronate on avascular necrosis of the femoral head according to disease stage and bone resorption activity. Journal of Orthopaedic Surgery and Research, 21(1), 188. https://doi.org/10.1186/s13018-025-06647-6
https://creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
https://creativecommons.org/licenses/by-nc-nd/4.0/
© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202602101675
https://urn.fi/URN:NBN:fi:oulu-202602101675
Tiivistelmä
Abstract
Background:
Avascular necrosis (AVN) of the femoral head is a progressive condition that leads to collapse of the femoral head in 85% of symptomatic patients when left untreated. As it is typically a disease that occurs among the younger population, the consequent arthroplasty of the hip is a radical procedure. In this study, we investigated the effect of intravenous zoledronate infusion in patients with avascular necrosis of the femoral head.
Methods:
This retrospective study included 94 hips diagnosed with AVN of the femoral head that were treated off-label with 4 mg intravenous zoledronate once or twice in 3-month intervals during the years 2007-2019 at Oulu University Hospital.
Results:
We found that 38% of the zoledronate-treated hips did not require arthroplasty; 75% of patients not requiring arthroplasty were men. Risk factors for arthroplasty were high Association Research Circulation Osseous (ARCO) stage, large volume of osteonecrosis and edema at baseline, 3, and 6 months of follow-up. High resorption activity indicated by higher levels of cross-linked carboxy- terminal telopeptide of type I collagen (ICTP) after zoledronate infusion in hips classified as ARCO IV predicted a poor outcome (p=0.002). The mean follow-up for those not requiring arthroplasty was 102.4 months.
Conclusion:
Zoledronate treatment is more likely to be effective in male patients with early-stage osteonecrosis (ARCO I–II), whereas advanced-stage disease (ARCO III–IV) may not respond well. Moreover, an accelerated bone resorption rate, indicated by elevated ICTP levels after zoledronate infusion, is associated with an increased risk of treatment failure.
Background:
Avascular necrosis (AVN) of the femoral head is a progressive condition that leads to collapse of the femoral head in 85% of symptomatic patients when left untreated. As it is typically a disease that occurs among the younger population, the consequent arthroplasty of the hip is a radical procedure. In this study, we investigated the effect of intravenous zoledronate infusion in patients with avascular necrosis of the femoral head.
Methods:
This retrospective study included 94 hips diagnosed with AVN of the femoral head that were treated off-label with 4 mg intravenous zoledronate once or twice in 3-month intervals during the years 2007-2019 at Oulu University Hospital.
Results:
We found that 38% of the zoledronate-treated hips did not require arthroplasty; 75% of patients not requiring arthroplasty were men. Risk factors for arthroplasty were high Association Research Circulation Osseous (ARCO) stage, large volume of osteonecrosis and edema at baseline, 3, and 6 months of follow-up. High resorption activity indicated by higher levels of cross-linked carboxy- terminal telopeptide of type I collagen (ICTP) after zoledronate infusion in hips classified as ARCO IV predicted a poor outcome (p=0.002). The mean follow-up for those not requiring arthroplasty was 102.4 months.
Conclusion:
Zoledronate treatment is more likely to be effective in male patients with early-stage osteonecrosis (ARCO I–II), whereas advanced-stage disease (ARCO III–IV) may not respond well. Moreover, an accelerated bone resorption rate, indicated by elevated ICTP levels after zoledronate infusion, is associated with an increased risk of treatment failure.
Kokoelmat
- Avoin saatavuus [43406]
Ellei muuten mainita, aineiston lisenssi on https://creativecommons.org/licenses/by-nc-nd/4.0/